Amicus Therapeutics Inc. has withdrawn its initial public offering amid difficult market conditions, the latest in a spate of biopharmaceutical companies to do so.
Amicus Therapeutics Inc. has withdrawn its initial public offering amid difficult market conditions, the latest in a spate of biopharmaceutical companies to do so.